EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Sustained remission with PD-1 and BTK inhibitors maintenance after chimeric antigen receptor T-cell therapy in CNS lymphoma

Lingzi Yu, Nana Ping, Rui Zou, Qian Zhu, Junhong Li, Xiao Zhang, Fan Xia, Jiajie He, Jiajie Tu, Danqing Kong, Depei Wu, Zhengming Jin und 1 weitere

Cancer Immunology, Immunotherapy · 2025

DOI: 10.1007/s00262-025-04236-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2025. Verfasst von Lingzi Yu und 12 weiteren Autor:innen. Beteiligte Einrichtung: The First Affiliated Hospital of Soochow University, No. 899, Pinghai Road, Gusu District, Suzhou, Jiangsu Province, China. Hauptthemen laut MEDLINE: Central Nervous System Neoplasms, Agammaglobulinaemia Tyrosine Kinase, Programmed Cell Death 1 Receptor, Immunotherapy, Adoptive. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Jiangsu Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Central Nervous System NeoplasmsAgammaglobulinaemia Tyrosine KinaseProgrammed Cell Death 1 ReceptorImmunotherapy, AdoptiveProtein Kinase InhibitorsReceptors, Chimeric AntigenLymphomaHumansFemaleMaleMiddle AgedAgedAdultRemission InductionRetrospective StudiesFollow-Up Studies

Stichwörter der Autor:innen

Bruton’s tyrosine kinase inhibitorCentral nervous system lymphomaChimeric antigen receptor T-cell therapyDuration of remissionProgrammed cell death protein-1 inhibitor

Substanzen

Agammaglobulinaemia Tyrosine KinaseProgrammed Cell Death 1 ReceptorProtein Kinase InhibitorsReceptors, Chimeric AntigenBTK protein, humanPDCD1 protein, human

Autor:innen und Institutionen

  • The First Affiliated Hospital of Soochow University, No. 899, Pinghai Road, Gusu District, Suzhou, Jiangsu Province, China.
  • National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, No. 899, Pinghai Road, Gusu District, Suzhou, Jiangsu Province, China.
  • Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, No. 899, Pinghai Road, Gusu District, Suzhou, Jiangsu Province, China.
  • Department of Pharmacy, The First Affiliated Hospital of Soochow University, No. 899, Pinghai Road, Gusu District, Suzhou, Jiangsu Province, China.
  • The First Affiliated Hospital of Soochow University, No. 899, Pinghai Road, Gusu District, Suzhou, Jiangsu Province, China. wudepei18@163.com.
  • National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, No. 899, Pinghai Road, Gusu District, Suzhou, Jiangsu Province, China. wu…

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Jiangsu Province

Zitieren

APA

Yu, L., Ping, N., Zou, R., Zhu, Q., Li, J., Zhang, X., Xia, F., He, J., Tu, J., Kong, D., Wu, D., Jin, Z., & Qu, C. (2025). Sustained remission with PD-1 and BTK inhibitors maintenance after chimeric antigen receptor T-cell therapy in CNS lymphoma. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-025-04236-4

Vancouver

Yu L, Ping N, Zou R, Zhu Q, Li J, Zhang X, et al. Sustained remission with PD-1 and BTK inhibitors maintenance after chimeric antigen receptor T-cell therapy in CNS lymphoma. Cancer Immunology, Immunotherapy. 2025. doi:10.1007/s00262-025-04236-4

BibTeX
@article{Yu2025,
  author = {Yu, Lingzi and Ping, Nana and Zou, Rui and Zhu, Qian and Li, Junhong and Zhang, Xiao and Xia, Fan and He, Jiajie and Tu, Jiajie and Kong, Danqing and Wu, Depei and Jin, Zhengming and Qu, Changju},
  title = {Sustained remission with PD-1 and BTK inhibitors maintenance after chimeric antigen receptor T-cell therapy in CNS lymphoma},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2025},
  doi = {10.1007/s00262-025-04236-4}
}
Kostenlos starten →